Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3

Manosuthi, Weerawat; Chimsuntorn, Sukanya; Likanonsakul, Sirirat; Sungkanuparph, Somnuek
January 2007
AIDS Research & Therapy;2007, Vol. 4, p1
Academic Journal
Background: Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of tavudine (d4T)/lamivudine 3TC)/nevirapine (NVP) is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected patients is limited. Methods: A retrospective cohort study was conducted among ART-naïve HIV-infected patients who were initiated a generic FDC of d4T/3TC/NVP between May 2004 and October 2005. Patients were categorized into 2 groups according to the baseline CD4 (group A: <50 cell/mm3 and group B: = 50 cell/mm3). Results: There were 204 patients with a mean ± SD age of 37.1 ± 8.9 years, 120 (58.8%) in group A and 84 (41.2%) in group B. Median (IQR) CD4 cell count was 6 (16-29) cells/mm3 in group A and 139 (92-198) cells/mm3 in group B. Intention-to-treat analysis at 48 weeks, 71.7% (86/120) of group A and 75.0% (63/84) of group B achieved plasma HIV RNA <50 copies/ml (P = 0.633). On treatment analysis, 90.5% (87/96) in group A and 96.9% (63/65) in group B achieved plasma HIV RNA <50 copies/ml (P = 0.206). At 12, 24, 36 and 48 weeks of ART, mean CD4 were 98, 142, 176 and 201 cells/mm3 in group A and 247, 301, 336 and 367 cells/mm3 in group B, respectively. There were no differences of probabilities to achieve HIV RNA <50 copies/ml (P = 0.947) and CD4 increment at 48 weeks between the two groups (P = 0.870). Seven (9.6%)patients in group A and 4 (8.5%) patients in group B developed skin reactions grade II or III (P = 1.000). ALT at 12 weeks was not different from that at baseline in both groups (P > 0.05). Conclusion: Initiation of FDC of d4T/3TC/NVP in HIV-infected patients with CD4 <50 and = 50 cells/mm3 has no different outcomes in terms of safety and efficacy. FDC of d4T/3TC/NVP can be effectively used in advance HIV-infected patients with CD4 <50 cells/mm3.


Related Articles

  • Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Moatti, J. P.; N’Doye, I; Hammer, S. M.; Hale, P.; Kazatchkine, M. // Nature Medicine;Dec2003, Vol. 9 Issue 12, p1449 

    Focuses on the attainable paradigm for antiretroviral (ARV) treatment for HIV infection in developing countries. Feasibility of accessing to antiretroviral treatment; Scarcity of the evidence of the impact of the distribution of ARVs on HIV-related risk behaviors; Motivations for attending...

  • Antiretroviral Therapy Reduces HIV Transmission in Discordant Couples in Rural Yunnan, China. He, Na; Duan, Song; Ding, Yingying; Rou, Keming; McGoogan, Jennifer M.; Jia, Manhong; Yang, Yuecheng; Wang, Jibao; Montaner, Julio S. G.; Wu, Zunyou // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background: Although HIV treatment as prevention (TasP) via early antiretroviral therapy (ART) has proven to reduce transmissions among HIV-serodiscordant couples, its full implementation in developing countries remains a challenge. In this study, we determine whether China's current HIV...

  • Global Good News: Many More Treated.  // AIDS Treatment News;1/28/2005, Issue 409, p6 

    Reports on the increase in the number of people receiving antiretroviral treatment for HIV in developing countries. Determinants of the improvement; Role of local governments in treatment delivery; Countries needing more progress relating to treatment.

  • Treatment of HIV/AIDS in resource-limited settings: Exploring the idea of universal test and treat. van der Horst, Charles; Herce, Michael // Infectious Disease News;Aug2013, Vol. 26 Issue 8, p14 

    The author presents his views on the guidelines released by the World Health Organization on the use of antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infection and argues that it is time to use the test-and-treat approach to treat HIV.

  • Online CME Quiz Questions: Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society-USA Panel.  // JAMA: Journal of the American Medical Association;7/25/2012, Vol. 308 Issue 4, p413 

    A quiz concerning the antiretroviral treatment of adult HIV infection is presented.

  • A broad rejuvenation.  // Nature Reviews Microbiology;Dec2013, Vol. 11 Issue 12, p815 

    As World AIDS Day approaches, and the thirtieth anniversary year of the isolation of HIV draws to a close, it is timely to reflect on the past, present and future of HIV/AIDS research.

  • Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment. Nunn, Amy S.; Fonseca, Elize M.; Bastos, Francisco I.; Gruskin, Sofia; Salomon, Joshua A. // PLoS Medicine;Nov2007, Vol. 4 Issue 11, pe305 

    Amy Nunn and colleagues analyze the cost of antiretroviral drugs in Brazil between 2001 and 2005 and discuss the implications for HIV treatment in other developing countries.

  • '3 by 5' makes progress but falls short. Roehr, Bob // Bay Area Reporter;7/7/2005, Vol. 35 Issue 27, p13 

    Reports on the possibility that the goal of the "3 by 5," program aimed at providing antiretroviral therapy to people living with HIV/AIDS in developing countries by the end of 2005 would not be met. Highlights of an interim report by the World Health Organization and UN-AIDS, released on June...

  • Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to? Kumarasamy, N.; Patel, Atul; Pujari, Sanjay // Indian Journal of Medical Research;Dec2011, Vol. 134 Issue 6, p787 

    With the rapid scale up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics